RT Journal Article
SR Electronic
T1 Combination Therapy with VP16 and Ethinylestradiol for Hormone-Refractory Prostate Cancer: Good Response with Tolerability
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 3737
OP 3745
VO 30
IS 9
A1 AZUMA, HARUHITO
A1 INAMOTO, TERUO
A1 TAKAHARA, KIYOSHI
A1 IBUKI, NAOKAZU
A1 KOYAMA, KOHEI
A1 UTIMOTO, SYNYA
A1 FUJISUE, YUTAKA
A1 UEHARA, HIROHUMI
A1 KOMURA, KAZUMASA
A1 NOMI, HAYAHITO
A1 UBAI, TAKANOBU
A1 KATSUOKA, YOJI
YR 2010
UL http://ar.iiarjournals.org/content/30/9/3737.abstract
AB Objectives: This study evaluated the safety profile and therapeutic value of a combination therapy of etoposide and ethinylestradiol, which is a novel treatment protocol for patients with hormone-refractory prostate cancer (HRPC). Patients and Methods: Patients were given etoposide (25 mg/day, daily) and ethinylestradiol (3 mg/day, daily) orally until disease progression or unacceptable toxicity. The response rate, survival and safety profiles were evaluated. Results: Between 2003 and 2009, 61 patients were enrolled. In terms of PSA levels, >70% of patients showed a >50% reduction (complete response [CR] 51%, partial response 23%) and >90% showed a clinical response. Of 58 patients with measurable lesions, 24% (14/58) showed a CR, and most of these patients (13/14, 93%) survived without recurrence with median response duration of 28 months Conclusion: The regimen was tolerable, with a significant improvement in quality of life, and produced an effective response in patients with HRPC.